Visikol is leveraging its 3Screen™ digital pathology tools to assist pharmaceutical companies with shifting the paradigm of tissue analysis from a human-driven qualitative approach to a computer-driven quantitative approach
Visikol CEO Dr. Michael Johnson has announced that through the rapid adoption of its 3Screen™ drug discovery services and strong pharmaceutical company partnerships that Visikol will far exceed its original 2018 revenue projections.
Enzyvant, a biopharmaceutical company focused on developing innovative treatments for patients with rare diseases, today announced that it has formed a partnership with Visikol, a contract research organization focused on digital pathology and drug discovery.
Expand its laboratory service footprint and its reagent manufacturing capability to meet increasing market demand for the company’s high content screening, digital pathology, and advanced drug discovery services
For as little as $500 per tissue sample, Visikol is now offering 3D tissue labeling and imaging services so that all researchers can easily and quickly acquire 3D information from their tissues. This service offering is part of Visikol’s 3Screen™ services and is as easy as sending a tissue sample and then receiving a USB drive with over 1,000 images.